Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 9/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23792670 | 0.88 | ALDH1A1 (0.47) | AAK1ALDH1A1GAARXFP1SMN1; SMN2 | |
| SCHEMBL23792871 | 0.86 | AAK1 (0.43) | AAK1ALDH1A1GAARXFP1SMN1; SMN2 | |
| SCHEMBL10194877 | 0.86 | HPGD (0.44) | GAARXFP1SMN1; SMN2POLBLMNA | |
| SCHEMBL18535060 | 0.86 | RXFP1 (0.42) | ALDH1A1GAARXFP1NPC1RAB9A | |
| SCHEMBL30517815 | 0.85 | POLB (0.53) | AAK1ALDH1A1GAAPOLB | |
| SCHEMBL3490024 | 0.85 | POLB (0.53) | AAK1ALDH1A1GAAPOLB | |
| SCHEMBL31012013 | 0.83 | ALDH1A1 (0.58) | AAK1ALDH1A1GAARXFP1SMN1; SMN2 | |
| SCHEMBL19032231 | 0.83 | ALDH1A1 (0.58) | AAK1ALDH1A1GAARXFP1SMN1; SMN2 | |
| SCHEMBL5962094 | 0.81 | CYP17A1 (0.49) | AAK1ALDH1A1GAASMN1; SMN2LMNA | |
| SCHEMBL20036928 | 0.81 | KCNQ4 (0.43) | AAK1ALDH1A1RXFP1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3536319-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-09-11 | — | — | EP | disclosed |
| US-8999966-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-04-07 | — | — | US | disclosed |
| US-8999966-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20130237518-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP | 2013-09-12 | — | — | US | disclosed |
| US-20130237518-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP | 2013-09-12 | — | — | US | disclosed |
| WO-2012058127-A2 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | SCHERING CORPORATION (US) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237518-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MAPK1, MAPK4, MAP3K20 | AAK1 359/4885ALDH1A1 741/4885GAA 3319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.